Literature DB >> 26334197

Sense and nonsense in the process of accreditation of a pathology laboratory.

Elodie Long-Mira1, Kevin Washetine1,2, Paul Hofman3,4.   

Abstract

The aim of accreditation of a pathology laboratory is to control and optimize, in a permanent manner, good professional practice in clinical and molecular pathology, as defined by internationally established standards. Accreditation of a pathology laboratory is a key element in fine in increasing recognition of the quality of the analyses performed by a laboratory and in improving the care it provides to patients. One of the accreditation standards applied to clinical chemistry and pathology laboratories in the European Union is the ISO 15189 norm. Continued functioning of a pathology laboratory might in time be determined by whether or not it has succeeded the accreditation process. Necessary requirements for accreditation, according to the ISO 15189 norm, include an operational quality management system and continuous control of the methods used for diagnostic purposes. Given these goals, one would expect that all pathologists would agree on the positive effects of accreditation. Yet, some of the requirements stipulated in the accreditation standards, coming from the bodies that accredit pathology laboratories, and certain normative issues are perceived as arduous and sometimes not adapted to or even useless in daily pathology practice. The aim of this review is to elaborate why it is necessary to obtain accreditation but also why certain requirements for accreditation might be experienced as inappropriate.

Entities:  

Keywords:  Accreditation; Clinical pathology; Constraints; Molecular pathology; Norm ISO 15189

Mesh:

Year:  2015        PMID: 26334197     DOI: 10.1007/s00428-015-1837-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

Review 1.  [Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques].

Authors:  Véronique Hofman; Marius Ilie; Virginie Gavric-Tanga; Virgine Lespinet; Mireille Mari; Sandra Lassalle; Catherine Butori; Céline Coelle; Olivier Bordone; Eric Selva; Aude Lamy; Jean-Christophe Sabourin; Paul Hofman
Journal:  Ann Pathol       Date:  2010-04-13       Impact factor: 0.407

2.  Quality: walk the walk.

Authors:  Timothy Craig Allen
Journal:  Arch Pathol Lab Med       Date:  2011-11       Impact factor: 5.534

Review 3.  Overview of the laboratory accreditation programme of the College of American Pathologists.

Authors:  K K Abu-Amero
Journal:  East Mediterr Health J       Date:  2002 Jul-Sep       Impact factor: 1.628

4.  Analytical difficulties facing today's regulatory laboratories: issues in method validation.

Authors:  James D MacNeil
Journal:  Drug Test Anal       Date:  2012-08       Impact factor: 3.345

5.  Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet).

Authors:  Elizabeth A M Matzke; Sheila O'Donoghue; Rebecca O Barnes; Helena Daudt; Stefanie Cheah; Aaron Suggitt; John Bartlett; Sambasivarao Damaraju; Randal Johnston; Leigh Murphy; Lois Shepherd; Anne-Marie Mes-Masson; Brent Schacter; Peter H Watson
Journal:  Biopreserv Biobank       Date:  2012-10       Impact factor: 2.300

6.  Review of proficiency testing performance of laboratories accredited by the College of American Pathologists.

Authors:  G A Hoeltge; J K Duckworth
Journal:  Arch Pathol Lab Med       Date:  1987-11       Impact factor: 5.534

7.  Refocusing the war on cancer: the critical role of personalized treatment.

Authors:  Anil Potti; Richard L Schilsky; Joseph R Nevins
Journal:  Sci Transl Med       Date:  2010-04-21       Impact factor: 17.956

8.  Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.

Authors:  Kathryn S Dyhdalo; Patrick L Fitzgibbons; Jeffery D Goldsmith; Rhona J Souers; Raouf E Nakhleh
Journal:  Arch Pathol Lab Med       Date:  2014-07       Impact factor: 5.534

9.  Role of a quality management system in improving patient safety - laboratory aspects.

Authors:  Lynn C Allen
Journal:  Clin Biochem       Date:  2013-05-03       Impact factor: 3.281

10.  The times have changed: molecular pathology is here to stay. A commentary on: analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma, by Lee et al. In this issue.

Authors:  J Han van Krieken; Gerald Hoefler
Journal:  Virchows Arch       Date:  2012-02-23       Impact factor: 4.064

View more
  12 in total

Review 1.  An Introduction to Starting a Biobank.

Authors:  Mitra D Harati; Ryan R Williams; Masoud Movassaghi; Amin Hojat; Gregory M Lucey; William H Yong
Journal:  Methods Mol Biol       Date:  2019

Review 2.  Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?

Authors:  Simon Heeke; Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 3.  Pathologists and liquid biopsies: to be or not to be?

Authors:  Paul Hofman; Helmut H Popper
Journal:  Virchows Arch       Date:  2016-08-23       Impact factor: 4.064

Review 4.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

Review 5.  ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

Review 6.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

7.  Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients.

Authors:  Elodie Long-Mira; Marius Ilie; Emmanuel Chamorey; Florence Leduff-Blanc; Henri Montaudié; Virginie Tanga; Maryline Allégra; Virginie Lespinet-Fabre; Olivier Bordone; Christelle Bonnetaud; Renaud Schiappa; Catherine Butori; Coraline Bence; Jean-Philippe Lacour; Véronique Hofman; Paul Hofman
Journal:  Oncotarget       Date:  2018-11-16

8.  Laboratory professionals' attitudes towards ISO 15189:2012 accreditation: an anonymous survey of three Croatian accredited medical laboratories.

Authors:  Ivana Lapić; Dunja Rogić; Matea Ivić; Marina Tomičević; Mirjana Mariana Kardum Paro; Lovorka Đerek; Ines Alpeza Viman
Journal:  Biochem Med (Zagreb)       Date:  2021-06-15       Impact factor: 2.313

9.  Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes.

Authors:  Elodie Long-Mira; Alexandra Picard-Gauci; Sandra Lassalle; Véronique Hofman; Salomé Lalvée; Virginie Tanga; Katia Zahaf; Christelle Bonnetaud; Virginie Lespinet; Olivier Camuzard; Henri Montaudié; Gilles Poissonnet; Thierry Passeron; Marius Ilié; Paul Hofman
Journal:  Diagnostics (Basel)       Date:  2022-03-19

Review 10.  Challenges and issues surrounding the use for translational research of human samples obtained during the COVID-19 pandemic from lung cancer patients.

Authors:  Paul Hofman
Journal:  Transl Lung Cancer Res       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.